These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8013987)

  • 41. Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders.
    Mobini N; Sarela A; Ahmed AR
    Ann Allergy Asthma Immunol; 1995 Feb; 74(2):119-28; quiz 128-33. PubMed ID: 7697470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
    Rütter A; Luger TA
    J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of intravenous immunoglobulin preparations (IVIG) in treatment of primary cell immunodeficiencies].
    Siwińska-Gołebiowska H; Czerwińska-Kartowicz I; Markiewicz K
    Postepy Hig Med Dosw; 2002; 56 Suppl():33-40. PubMed ID: 12661412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous immunoglobulin: a review.
    Eibl MM; Wedgwood RJ
    Immunodefic Rev; 1989; 1 Suppl():1-42. PubMed ID: 2698646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?
    Crow AR; Lazarus AH
    Transfus Med Rev; 2008 Apr; 22(2):103-16. PubMed ID: 18353251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous immunoglobulin therapy in dermatologic disorders.
    Cakmak SK; Gül U; Gönül M; Kiliç A; Soylu S
    Inflamm Allergy Drug Targets; 2008 Jun; 7(2):75-84. PubMed ID: 18691136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.
    Ephrem A; Misra N; Hassan G; Dasgupta S; Delignat S; Duong Van Huyen JP; Chamat S; Prost F; Lacroix-Desmazes S; Kavery SV; Kazatchkine MD
    Clin Exp Med; 2005 Dec; 5(4):135-40. PubMed ID: 16362793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Use of intravenous immunoglobulins in pediatrics].
    Duse M; Plebani A; Crispino P; Ugazio AG
    Pediatr Med Chir; 1991; 13(2):117-25. PubMed ID: 1896376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics.
    Villanueva G; de Jong JL; McNeer JL
    Pediatr Ann; 2017 Jan; 46(1):e13-e18. PubMed ID: 28079913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hematologic toxicities associated with intravenous immunoglobulin therapy.
    Baxley A; Akhtari M
    Int Immunopharmacol; 2011 Nov; 11(11):1663-7. PubMed ID: 21843660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of action of intravenous immunoglobulin (IVIG).
    Kazatchkine MD; Bellon B; Kaveri SV
    Mult Scler; 2000 Oct; 6 Suppl 2():S24-6; discussion S33. PubMed ID: 11188775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases.
    Blank M; Bashi T; Shoenfeld Y
    Methods Mol Biol; 2014; 1060():353-61. PubMed ID: 24037850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.
    Bayry J; Dasgupta S; Misra N; Ephrem A; Duong Van Huyen JP; Delignat S; Hassan G; Caligiuri G; Nicoletti A; Lacroix-Desmazes S; Kazatchkine MD; Kaveri S
    Int Immunopharmacol; 2006 Apr; 6(4):528-34. PubMed ID: 16504915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.
    Wong PH; White KM
    Clin Rev Allergy Immunol; 2016 Dec; 51(3):303-314. PubMed ID: 26142065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The use of IVIG in pediatric oncohematology and hematopoietic stem cell transplantation].
    Kałwak K
    Pol Merkur Lekarski; 2011 Jun; 30(180):405-8. PubMed ID: 21751548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders.
    Imbach P; Lazarus AH; Kühne T
    Vox Sang; 2010 Apr; 98(3 Pt 2):385-94. PubMed ID: 19821958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High dose intravenous gammaglobulins in autoimmune disorders: mode of action and therapeutic uses.
    Etzioni A; Pollack S
    Autoimmunity; 1989; 3(4):307-15. PubMed ID: 2485083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.